Product Description
CF-370 is an engineered lysin therapeutic candidate with potent activity against Pseudomonas aeruginosa (“P. aeruginosa”). (Sourced by: https://www.contrafect.com/pipeline/cf-370)
Mechanisms of Action: Gram- Bacteria Degrader
Novel Mechanism: Yes
Modality: Coagulation Factor
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ContraFect
Company Location: YONKERS NY 10701
Company CEO: Roger J. Pomerantz
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Pseudomonas Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|